Compare TIC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIC | MESO |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | Australia |
| Employees | 6060 | 81 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | N/A | N/A |
| Metric | TIC | MESO |
|---|---|---|
| Price | $8.53 | $15.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $11.20 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 212.7K |
| Earning Date | 05-06-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $44.09 | $629.74 |
| Revenue Next Year | $4.40 | $30.65 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.36 | $9.88 |
| 52 Week High | $14.94 | $21.50 |
| Indicator | TIC | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 57.83 | 50.91 |
| Support Level | $6.55 | $14.44 |
| Resistance Level | $9.88 | $16.37 |
| Average True Range (ATR) | 0.42 | 0.48 |
| MACD | 0.21 | 0.10 |
| Stochastic Oscillator | 70.97 | 61.26 |
TIC Solutions Inc is a provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. It provides mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings and public infrastructure. The company's services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. It operates in North America and serve both public- and private-sector clients. Its public-sector clients include federal, state, and municipal agencies, public utilities, and environmental regulators. Its private-sector clients span industrial, infrastructure, construction, and real estate end markets.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.